[HTML][HTML] What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - frontiersin.org
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

The Therapeutic Pipeline for Pseudomonas aeruginosa Infections

LL Burrows - ACS infectious diseases, 2018 - ACS Publications
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen, designated by the
World Health Organization as a critical priority for development of new therapeutics due to …

[HTML][HTML] Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel …

N Sathe, P Beech, L Croft, C Suphioglu, A Kapat… - Infectious Medicine, 2023 - Elsevier
Pseudomonas aeruginosa is an aerobic Gram-negative rod-shaped bacterium with a
comparatively large genome and an impressive genetic capability allowing it to grow in a …

[HTML][HTML] The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update

D Reynolds, M Kollef - Drugs, 2021 - Springer
Pseudomonas aeruginosa is a Gram-negative bacterial pathogen that is a common cause of
nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and …

[HTML][HTML] How to manage Pseudomonas aeruginosa infections

M Bassetti, A Vena, A Croxatto, E Righi, B Guery - Drugs in context, 2018 - ncbi.nlm.nih.gov
Infections with Pseudomonas aeruginosa have become a real concern in hospital-acquired
infections, especially in critically ill and immunocompromised patients. The major problem …

[HTML][HTML] Emerging therapies against infections with Pseudomonas aeruginosa

B Tümmler - F1000Research, 2019 - ncbi.nlm.nih.gov
Infections with Pseudomonas aeruginosa have been marked with the highest priority for
surveillance and epidemiological research on the basis of parameters such as incidence …

[HTML][HTML] The Building Blocks of Antimicrobial Resistance in Pseudomonas aeruginosa: Implications for Current Resistance-Breaking Therapies

RF Langendonk, DR Neill, JL Fothergill - Frontiers in Cellular and …, 2021 - frontiersin.org
P. aeruginosa is classified as a priority one pathogen by the World Health Organisation, and
new drugs are urgently needed, due to the emergence of multidrug-resistant (MDR) strains …

[HTML][HTML] Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections

DRA Sanya, D Onésime, G Vizzarro, N Jacquier - BMC microbiology, 2023 - Springer
The opportunistic human pathogen Pseudomonas aeruginosa is the causal agent of a wide
variety of infections. This non-fermentative Gram-negative bacillus can colonize zones …

[HTML][HTML] It's Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa

P Behzadi, Z Baráth, M Gajdács - Antibiotics, 2021 - mdpi.com
Pseudomonas aeruginosa is the most frequent cause of infection among non-fermenting
Gram-negative bacteria, predominantly affecting immunocompromised patients, but its …

Recent trends and challenges to overcome Pseudomonas aeruginosa infections

A Ammazzalorso, A Granese… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Pseudomonas aeruginosa (PA) is a Gram-negative bacterium that can cause a
wide range of severe infections in immunocompromised patients. The most difficult …